Alnylam Pharma gets US patent for RNAi therapeutic (PharmaBiz)

Alnylam Pharma gets US patent for RNAi therapeutic (PharmaBiz)
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, has announced that a new key fundamental patent from its exclusively held “Tuschl II” patent series was issued by the United States Patent and Trademark Office (USPTO).